PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Restoring function in exhausted CD8 T cells during chronic viral infection

Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,259

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967

Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor

Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589

Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges

Zhou, S., Xie, J., Huang, Z., Deng, L., Wu, L., Yu, J., & Meng, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.043 · Cited by 35

Evolving adoptive cellular therapies in urological malignancies

Wong, Y. N. S., Joshi, K., Pulè, M. A., Peggs, K. S., Swanton, C., Quezada, S. A., & Linch, M. D. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30327-3 · Cited by 33

LINC00152 mediates CD8+ T-cell infiltration in gastric cancer through binding to EZH2 and regulating the CXCL9, 10/CXCR3 axis

Ou, J., Lei, P., Yang, Z., Yang, M. G., Luo, L.-M., Mo, H., Luo, G., & He, J. (2021) · Journal of Molecular Histology · doi:10.1007/s10735-021-09967-z · Cited by 33

Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age

Seaton, G., Smith, H., Brancale, A., Westwell, A. D., & Clarkson, R. W. E. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01922-8 · Cited by 32

PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer

Chen, H., Jiang, T., Lin, F.-Y., Guan, H., Zheng, J., Liu, Q., Du, B., Huang, Y., & Lin, X. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107929 · Cited by 32

XIST/miR-34a-5p/PDL1 axis regulated the development of lung cancer cells and the immune function of CD8+ T cells

Li, J., Che, L., Xu, C., Lu, D., Xu, Y., Liu, M., & Chai, W. (2022) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2021.2019274 · Cited by 31

Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy

Hinrichs, C. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1294 · Cited by 30

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides

Nakata, J., Nakajima, H., Hayashibara, H., Imafuku, K., Morimoto, S., Fujiki, F., Motooka, D., Okuzaki, D., Hasegawa, K., Hosen, N., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26338 · Cited by 30

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

D’Souza, A., Hari, P., Pasquini, M. C., Braun, T., Johnson, B., Lundy, S. K., Couriel, D. R., Hamadani, M., Magenau, J. M., Dhakal, B., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.04.005 · Cited by 30

Therapeutic targeting of immune checkpoints with small molecule inhibitors.

Smith, W. M., Purvis, I. J., Bomstad, C. N., Labak, C. M., Velpula, K. K., Tsung, A. J., Regan, J. N., Venkataraman, S., Vibhakar, R., & Asuthkar, S. (2019) · Europe PMC (PubMed Central) · Cited by 30

PD-1 immunobiology in glomerulonephritis and renal cell carcinoma

Curran, C. S., & Kopp, J. B. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02257-6 · Cited by 30

Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model

Veerman, R. E., Akpinar, G. G., Offens, A., Steiner, L., Larssen, P., Lundqvist, A., Karlsson, M. C. I., & Gabrielsson, S. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0540 · Cited by 30

Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise

Bird, B., Nally, K., Ronan, K. E., Clarke, G. A., Amu, S., Almeida, A. S., Flavin, R., & Finn, S. P. (2022) · Diagnostics · doi:10.3390/diagnostics12010124 · Cited by 29

Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition

Wenthe, J., Naseri, S., Hellström, A.-C., Moreno, R., Ullenhag, G. J., Alemany, R., Lövgren, T., Eriksson, E., & Loskog, A. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.01.003 · Cited by 29

Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models

Cui, S. (2017) · Medical Science Monitor · doi:10.12659/msm.902426 · Cited by 29

The synergistic interaction between the calcineurin B subunit and IFN-γ enhances macrophage antitumor activity

Su, Z., Yang, R., Zhang, W., Xu, L., Zhong, Y., Yin, Y., Cen, J., DeWitt, J. P., & Wei, Q. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.92 · Cited by 29

Leveraging STING, Batf3 Dendritic Cells, CXCR3 Ligands, and Other Components Related to Innate Immunity to Induce a “Hot” Tumor Microenvironment That Is Responsive to Immunotherapy

Reschke, R., & Olson, D. (2022) · Cancers · doi:10.3390/cancers14102458 · Cited by 28

Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma

Woods, K., Knights, A. J., Anaka, M., Schittenhelm, R. B., Purcell, A. W., Behren, A., & Cebon, J. S. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0111-7 · Cited by 29

The duality of CXCR3 in glioblastoma: unveiling autocrine and paracrine mechanisms for novel therapeutic approaches

Chan, T. Y. H., Wong, J. S. Y., Kiang, K. M. Y., Sun, C. W. Y., & Leung, G. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06354-2 · Cited by 28

Genetic variation in IRF 4 expression modulates growth characteristics, tyrosinase expression and interferon‐gamma response in melanocytic cells

Chhabra, Y., Yong, X. L. H., Fane, M. E., Soogrim, A., Lim, W., Mahiuddin, D. N., Kim, R. S. Q., Ashcroft, M. M., Beatson, S. A., Ainger, S. A., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12620 · Cited by 30

DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors

Chung, J., Ramani, V., Kobayashi, M., Fattah, F. J., Popat, V., Zhang, S., Cruz, P. D., Gerber, D. E., & Ariizumi, K. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2360 · Cited by 28

Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity

Clark, M. L., Simeonov, K. P., Mowel, W. K., Michieletto, M. F., Joannas, L. D., Wright, J. M., Erickson, I., Johnson, L. R., Krishnan, R., de la Fuente‐Núñez, C., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.06.006 · Cited by 29

Coinhibitory molecules in cancer biology and therapy

D, S. M. M., Benna, C., & Pilati, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.003 · Cited by 27

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses

Zang, H., Peng, J., Zheng, H., & Fan, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00515 · Cited by 26

IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab

Sakatani, T., Kita, Y., Fujimoto, M., Sano, T., Hamada, A., Nakamura, K. D., Takada, H., Goto, T., Sawada, A., Akamatsu, S., et al. (2022) · Cancers · doi:10.3390/cancers14020263 · Cited by 26

IFNγ producing CD8+T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas

Buferne, M., Chasson, L., Grange, M., Mas, A., Arnoux, F., Bertuzzi, M., Naquet, P., Leserman, L., Schmitt‐Verhulst, A., & Auphan‐Anezin, N. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.974959 · Cited by 25

PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells

Kumar, R., Yu, F. H. Z., Zhen, Y.-H., Li, B., Wang, J., Yang, Y., Ge, H., Hu, P., & Jin, X. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s130131 · Cited by 25

Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model

Chitphet, K., Geary, S. M., Chan, C. H. F., Simons, A. L., Weiner, G. J., & Salem, A. K. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01108 · Cited by 25

Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy

Jarvis, E.-M., Collings, S., Authier-Hall, A., Dasyam, N., Luey, B., Nacey, J. N., Painter, G. F., Delahunt, B., Hermans, I. F., & Weinkove, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748741 · Cited by 24

Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer

KUMAGAI, Y., Futoh, Y., Miyato, H., Ohzawa, H., Yamaguchi, H., Saito, S., Kurashina, K., Hosoya, Y., Lefor, A. K., Sata, N., et al. (2022) · In Vivo · doi:10.21873/invivo.12811 · Cited by 24

The CXCL10/CXCR3 Pathway Contributes to the Synergy of Thermal Ablation and PD-1 Blockade Therapy against Tumors

Xiao, W., Huang, H., Zheng, P., Liu, Y., Chen, Y., Chen, J., Zheng, X. W., Chen, L., & Jiang, J. (2023) · Cancers · doi:10.3390/cancers15051427 · Cited by 24

Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses

Hu, X., Hu, Z., Zhang, H., Zhang, N., Feng, H., Jia, X., Zhang, C., & Cheng, Q. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216466 · Cited by 24

Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma

Isazadeh, A., Hajazimian, S., Garshasbi, H., Shadman, B., Baghbanzadeh, A., Chavoshi, R., Taefehshokr, S., Jadid, M. F. S., Hajiasgharzadeh, K., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29905 · Cited by 23

Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma

Xie, L., Liu, M., Cai, M., Huang, W., Guo, Y., Liang, L., Cai, W., Liu, J., Liang, W., Tan, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114254 · Cited by 23

Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells

Hernández-López, P., van Diest, E., Brázda, P., Heijhuurs, S., Meringa, A. D., Heyningen, L. H. V., Riillo, C., Schwenzel, C., Zintchenko, M., Johanna, I., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01665-0 · Cited by 23

IFNγ induces JAK1/STAT1/p65 NFκB-dependent interleukin-8 expression in ovarian cancer cells, resulting in their increased migration

Padmanabhan, S., Gaire, B., Zou, Y., Uddin, M. M., DeLeon, D., & Vancurova, I. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106093 · Cited by 22

Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer

Ren, X., Cui, H., Wu, J., Zhou, R., Wang, N., Liu, D., Xie, X., Zhang, H., Liu, D., Ma, X., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4755 · Cited by 23

Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials

Jiang, M., Fiering, S., & Shao, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1153066 · Cited by 23

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model

Liu, H., Weber, A. M., Morse, J. M., Kodumudi, K. N., Scott, E. N., Mullinax, J. E., Sarnaik, A. A., & Pilon‐Thomas, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196033 · Cited by 22

Oral administration of a whole glucan particle (WGP)-based therapeutic cancer vaccine targeting macrophages inhibits tumor growth

He, L., Bai, Y., Xia, L., Pan, J., Sun, X. Y., Zhu, Z., Ding, J., Qi, C., & Tang, C. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03136-7 · Cited by 22

Identification of Key Genes in Thyroid Cancer Microenvironment

Zhao, K., Yang, H., Kang, H., & Wu, A. (2019) · Medical Science Monitor · doi:10.12659/msm.918519 · Cited by 21

Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms

Etxeberría, I., Olivera, I., Bolaños, E., Cirella, A., Teijeira, Á., Berraondo, P., & Melero, I. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0464-1 · Cited by 23

TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice

Tanaka, Y., Wada, H., Goto, R., Osada, T., Yamamura, K., Fukaya, S., Shimizu, A., Okubo, M., Minamiguchi, K., Ikizawa, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74187-6 · Cited by 21

Infiltrating T cells promote renal cell carcinoma (RCC) progressionviaaltering the estrogen receptor β-DAB2IP signals

Yeh, C., Ou, Z.-Y., Xiao, G., Guancial, E. A., & Yeh, S. (2015) · Oncotarget · doi:10.18632/oncotarget.5884 · Cited by 21

Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report

Merhi, M., Raza, A., Inchakalody, V. P., Siveen, K. S., Kumar, D., Sahir, F., Mestiri, S., Hydrose, S., Allahverdi, N., Jalis, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001278 · Cited by 21

Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer

Hosseinzadeh, S., Imani, M., Pourfarzi, F., Jafari, N., Abediankenari, S., & Safarzadeh, E. (2024) · Medical Oncology · doi:10.1007/s12032-024-02326-4 · Cited by 20

A Task Force Against Local Inflammation and Cancer: Lymphocyte Trafficking to and Within the Skin

Lafouresse, F., & Groom, J. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02454 · Cited by 23

Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers

Chen, L., Qiao, D., Wang, J., Tian, G., & Wang, M. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.10.002 · Cited by 21

A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy

Miyasaka, Y., Sato, H., Okano, N., Kubo, N., Kawamura, H., & Ohno, T. (2021) · Cancers · doi:10.3390/cancers14010203 · Cited by 21

Innate lymphoid cells: A potential link between microbiota and immune responses against cancer

Panda, S. K., & Colonna, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.003 · Cited by 21

Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors

Alserawan, L., Mulet, M., Anguera, G., Riudavets, M., Zamora, C., Osuna‐Gómez, R., Serra-López, J., Joaquín, A. B., Sullivan, I., Majem, M., et al. (2024) · Cancers · doi:10.3390/cancers16091759 · Cited by 18

Enhancing the Efficacy of Adoptive Cellular Therapy By Targeting Tumor-InDuced Immunosuppression

Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Neeson, P. J., & Darcy, P. K. (2015) · Immunotherapy · doi:10.2217/imt.15.16 · Cited by 18

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

Ascierto, P. A., Grimaldi, A. M., Acquavella, N., Borgognoni, L., Calabrò, L., Cascinelli, N., Cesano, A., Vecchio, M. D., Eggermont, A. M. M., Faries, M. B., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-137 · Cited by 18

Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation

Champagne, J., Nielsen, M. M., Feng, X., Navarro, J. M., Pataskar, A., Voogd, R., Giebel, L., Nagel, R., Berenst, N., Fumagalli, A., et al. (2025) · Immunity · doi:10.1016/j.immuni.2024.12.004 · Cited by 17

Downregulation of Interferon-γ Receptor Expression Endows Resistance to Anti–Programmed Death Protein 1 Therapy in Colorectal Cancer

Lv, C., Yuan, D., & Cao, Y. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000284 · Cited by 17

Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients

Gawali, V. S., Chimote, A. A., Newton, H. S., Feria, M. G., Chirra, M., Janssen, E. M., Wise-Draper, T. M., & Conforti, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.742862 · Cited by 17

Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study

Du, X., Wen, S., Shi, R., Xia, J., Wang, R., Zhang, Y., Pan, B., Wu, X., Zhu, W., Feng, J., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10502-4 · Cited by 17

The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

Attias, M., & Piccirillo, C. A. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16313 · Cited by 17

Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report

Occhipinti, M. A., Falcone, R., Onesti, C. E., & Marchetti, P. (2018) · Drug Safety - Case Reports · doi:10.1007/s40800-018-0078-z · Cited by 17

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

Voss, M. H., Azad, A. A., Hansen, A. R., Gray, J. E., Welsh, S. J., Song, X., Kuziora, M., Meinecke, L., Blando, J. M., Achour, I., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4115 · Cited by 16

IFNγ-Induced Bcl3, PD-L1 and IL-8 Signaling in Ovarian Cancer: Mechanisms and Clinical Significance

Reddy, S. P., Sadia, F. Z., Vančura, A., & Vancurova, I. (2024) · Cancers · doi:10.3390/cancers16152676 · Cited by 16

Bioanalytical Qualification of Clinical Biomarker Assays in Plasma Using A Novel Multi-Analyte Simple Plex ™ Platform

Gupta, V., Davancaze, T., Good, J., Kalia, N., Anderson, M., Wallin, J. J., Brady, A., Song, A., & Xu, W. (2016) · Bioanalysis · doi:10.4155/bio-2016-0196 · Cited by 16

The Possible Role of PD-1 Protein in Ganoderma lucidum –Mediated Immunomodulation and Cancer Treatment

Wang, G., Wang, L., Zhou, J., & Xu, X. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419880275 · Cited by 16

Hemagglutinating virus of Japan‐envelope containing programmed cell death‐ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma

Sugii, N., Matsuda, M., Okumura, G., Shibuya, A., Ishikawa, E., Kaneda, Y., & Matsumura, A. (2020) · Cancer Science · doi:10.1111/cas.14721 · Cited by 16

High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma

Burkard, M., Niessner, H., Leischner, C., Piotrowsky, A., Renner, O., Marongiu, L., Lauer, U. M., Busch, C., Sinnberg, T. W., & Venturelli, S. (2023) · Cells · doi:10.3390/cells12020254 · Cited by 17

New monoclonal antibodies on the horizon in multiple myeloma

O’Donnell, E., & Raje, N. S. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716682490 · Cited by 16

CD56−CD16+ NK cells from HIV-infected individuals negatively regulate IFN-γ production by autologous CD8+ T cells

Ma, M., Yin, X., Zhao, X. F., Guo, C., Zhu, X., Liu, T., Yang, M., Zhang, Z., Fu, Y., Liu, J., et al. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3a0819-171rr · Cited by 16

The Tumor Microenvironment in Hepatocellular Carcinoma

Nagaoka, K., Tanaka, Y., & Hino, O. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_66 · Cited by 16

Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives

Zhang, B., Tan, H., Kuang, J., Zhou, B., Liang, S., Pang, X. Y., Ouyang, Y., Zhang, Z., Long, Y., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02487-4 · Cited by 15

Mucosal microbiota characterization in gastric cancer identifies immune-activated–related transcripts relevant gastric microbiome signatures

Qian, C., Jiang, H., Peng, Z., Sun, X., & Zhang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435334 · Cited by 15

HMGB3 Contributes to Anti‐PD‐1 Resistance by Inhibiting IFN‐γ‐Driven Ferroptosis in TNBC

Luo, B., Zheng, H., Liang, G., Luo, Y. Q., Zhang, Q., & Li, X. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23861 · Cited by 15

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy

Parmiani, G., Maccalli, C., & Maio, M. (2015) · Vaccines · doi:10.3390/vaccines3020420 · Cited by 15

Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility

Dobiášová, B., & Mego, M. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s231502 · Cited by 15

A novel immune-related prognostic signature in epithelial ovarian carcinoma

Su, T., Zhang, P., Zhao, F., & Zhang, S. (2021) · Aging · doi:10.18632/aging.202792 · Cited by 15

Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy

Christenson, M., Song, C. S., Liu, Y., & Chatterjee, B. (2022) · Cancers · doi:10.3390/cancers14040892 · Cited by 15

Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases

Yang, G., Xing, L., & Sun, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.852811 · Cited by 15

Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas

Stinson, J. A., Sheen, A. M., Momin, N., Hampel, J., Bernstein, R., Kamerer, R. L., Fadl-Alla, B. A., Samuelson, J., Fink, E., Fan, T. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0006 · Cited by 15

Novel Treatments in Development for Melanoma

Bernatchez, C., Cooper, Z. A., Wargo, J. A., Hwu, P., & Lizee, G. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_16 · Cited by 15

The Ins and Outs of Chemokine-Mediated Immune Cell Trafficking in Skin Cancer

Yam, A. O. W., & Chtanova, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00386 · Cited by 15

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Letter

Radvanyi, L. G., Pilon‐Thomas, S., Peng, W., Sarnaik, A. A., Mulé, J. J., Weber, J. S., & Hwu, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1054 · Cited by 15

An Engineered Probiotic Consortium Based on Quorum‐Sensing for Colorectal Cancer Immunotherapy

Guo, Y., Gao, M., Wang, L., Yuan, H., Yin, J., Wu, J., Gao, X., Zhu, Z., Zhang, Y., Wang, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202512744 · Cited by 14

Pancreatic cancer is associated with aberrant monocyte function and successive differentiation into macrophages with inferior anti-tumour characteristics

Juusola, M., Kuuliala, K., Kuuliala, A., Mustonen, H. K., Vähä-Koskela, M. J. V., Puolakkainen, P. A., & Seppänen, H. E. (2021) · Pancreatology · doi:10.1016/j.pan.2020.12.025 · Cited by 14

PD-1Hi CAR-T cells provide superior protection against solid tumors

Sailer, C. J., Hong, Y., Dahal, A., Ryan, A. T., Mir, S., Gerber, S. A., Reagan, P. M., & Kim, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1187850 · Cited by 15

Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report

Mao, S., Zhang, J., Guo, Y., Zhang, Z., Wu, Y., Zhang, W., Wang, L., Geng, J., Yan, Y., & Yao, X. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s181122 · Cited by 14

Functional tumor specific CD8 + T cells in spleen express a high level of PD-1

Wang, Z., Chen, T., Lin, W., Zheng, W., Chen, J., Huang, F., & Xie, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106242 · Cited by 14

Rare Earth Nanoprobes for Targeted Delineation of Triple Negative Breast Cancer and Enhancement of Radioimmunotherapy

Ming, Z., Zhang, Y., Song, L., Chen, M., Lin, L., He, Y., Liu, W., Zhu, Y., Zhang, Y., & Zhang, G. (2024) · Advanced Science · doi:10.1002/advs.202309992 · Cited by 13

Switching on the green light for chimeric antigen receptor T‐cell therapy

Mardiana, S., Lai, J., House, I. G., Beavis, P. A., & Darcy, P. K. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1046 · Cited by 13

Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing

Ouchi, Y., Patil, A., Tamura, Y., Nishimasu, H., Negishi, A., Paul, S. K., Takemura, N., Satoh, T., Kimura, Y., Kurachi, M., et al. (2018) · International Immunology · doi:10.1093/intimm/dxy006 · Cited by 13

Immune checkpoint protein PD-L1 promotes transcription of angiogenic and oncogenic proteins IL-8, Bcl3, and STAT1 in ovarian cancer cells

Reddy, S. P., Sham, R., Smith, K., Gaire, B., Vančura, A., & Vancurova, I. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108339 · Cited by 12

Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma

Milenova, I. E., González, M. L., Quixabeira, D. C. A., Santos, J. M., Cervera-Carrascón, V., Dong, W., Hemminki, A., van Beusechem, V. W., van de Ven, R., & de Gruijl, T. D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.277 · Cited by 12

Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders

Lasheen, N. N., Allam, S., Elgarawany, A., Aswa, D. W., Mansour, R., & Farouk, Z. E. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00933-4 · Cited by 12

Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches

Aquino, A., & Franzese, O. (2025) · Cancers · doi:10.3390/cancers17091547 · Cited by 13

Biomarkers in immunotherapy: literature review and future directions

Pharaon, R. R., Koczywas, M. A., Salgia, S. K., Mohanty, A. R., & Massarelli, E. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.15 · Cited by 11

IFNγ induces Bcl3 expression by JAK1/STAT1/p65 signaling, resulting in increased IL‐8 expression in ovarian cancer cells

Gaire, B., Padmanabhan, S., Zou, Y., Uddin, M. M., Reddy, S. U., & Vancurova, I. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13624 · Cited by 10

Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma

Hasanov, M., Kiany, S., Forget, M., Bassett, R. L., Davies, M. A., Diab, A. K., Gershenwald, J. E., Glitza, I. C., Lee, J. E., Lucci, A., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2546402 · Cited by 10

Current landscape and tailored management of immune-related adverse events

Liu, W., Luo, Z., Liu, Y., & Sun, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1078338 · Cited by 10

Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer

Lassoued, W., Madan, R. A., Xue, E., Burnett, D., Canubas, K., Bailey, S., Marté, J. L., Tsai, Y.-T., Donahue, R. N., Turkbey, I. B., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010851 · Cited by 10

Macrophage repolarization by immune checkpoint blockade drives T cell engagement in the tumor microenvironment

Kwok, T., Silva, I., Korpe, S., Dong, H., & Lancaster, J. N. (2025) · iScience · doi:10.1016/j.isci.2025.113538 · Cited by 10

Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors

Launspach, M., Macos, J., Afzal, S., Hohmann, J., Appis, M. L., Pilgram, M., Beez, S., Ohlendorf, E., van der Ven, C. F. T., Lachiheb, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67328-w · Cited by 10

The CXCL10/CXCR3 axis is essential for sustaining immunological dormancy in triple-negative breast cancer

Yilmaz, A., Haerri, L., Granda, M. E., Coquoz, O., Lan, Q., & Rüegg, C. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-00903-6 · Cited by 10

Abstract 4385: PD-1 blockade enhances T-cell migration to tumor through induction of IFN-γ inducible chemokines

Peng, W., Liu, C., Xu, C., Chen, J., Lou, Y., Overwijk, W. W., Lizee, G. A., Yagita∥, H., & Hwu, P. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-4385

Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer

Peng, W., Lizee, G. A., & Hwu, P. (2013) · OncoImmunology · doi:10.4161/onci.22691 · Cited by 36

PD-1 blockade reverts motility arrest of transferred tumor-infiltrating CD8+ T cells in adoptive cell transfer immunotherapy (TUM7P.1014)

Mehta, G. U., Sukumar, M., McGavern, D. B., & Restifo, N. P. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.194.supp.142.3

Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner

Shi, L. Z., Goswami, S., Fu, T., Guan, B., Chen, J., Xiong, L., Zhang, J., Tang, D. N., Zhang, X., Vence, L. M., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0873 · Cited by 47

Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy

Kobold, S., Grassmann, S. A., Chaloupka, M., Lampert, C., Wenk, S., Kraus, F. B. T., Rapp, M., Duewell, P., Zeng, Y., Schmollinger, J. C., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv146 · Cited by 121